• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Compugen Ltd.

    2/14/25 4:10:22 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    COMPUGEN LTD

    (Name of Issuer)


    Ordinary Shares, par value NIS 0.01

    (Title of Class of Securities)


    M25722105

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    M25722105


    1Names of Reporting Persons

    BRISTOL MYERS SQUIBB CO
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,840,136.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,840,136.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,840,136.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.06 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  The percentage ownership interest is determined based on 89,237,465 Ordinary Shares of the Issuer which were outstanding as of June 30, 2024, as disclosed to the Reporting Person by the Issuer on August 6, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    COMPUGEN LTD
    (b)Address of issuer's principal executive offices:

    26 Harokmim Street, Holon, Israel, 8558549
    Item 2. 
    (a)Name of person filing:

    Bristol-Myers Squibb Company
    (b)Address or principal business office or, if none, residence:

    Route 206 & Province Line Road Princeton, NJ 08543
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Ordinary Shares, par value NIS 0.01
    (e)CUSIP No.:

    M25722105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on the cover page.
    (b)Percent of class:

    See response to Item 11 on the cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on the cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on the cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on the cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BRISTOL MYERS SQUIBB CO
     
    Signature:/s/ Amy Fallone
    Name/Title:Amy Fallone / Corporate Secretary
    Date:02/14/2025
    Get the next $CGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGEN

    DatePrice TargetRatingAnalyst
    1/13/2025$4.00Outperform
    Oppenheimer
    8/5/2022$2.00Buy → Hold
    Jefferies
    2/25/2022$17.00 → $14.00Outperform
    Oppenheimer
    2/25/2022$16.00 → $9.00Outperform
    SVB Leerink
    More analyst ratings

    $CGEN
    SEC Filings

    See more
    • SEC Form 6-K filed by Compugen Ltd.

      6-K - COMPUGEN LTD (0001119774) (Filer)

      5/19/25 7:00:36 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Compugen Ltd.

      6-K - COMPUGEN LTD (0001119774) (Filer)

      5/13/25 7:00:06 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Compugen Ltd.

      20-F - COMPUGEN LTD (0001119774) (Filer)

      3/4/25 7:30:38 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compugen Reports First Quarter 2025 Results

      Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCOSolid financial position with cash runway expected to fund operations into 2027Key leadership transitions to take effect in September 2025HOLON, Israel, May 19, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage ca

      5/19/25 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compugen Announces Leadership Transitions Effective September 2025

      Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of DirectorsEran Ophir, Ph.D., appointed as President and Chief Executive Officer and will join the Board of DirectorsPaul Sekhri to step down as Chair of the Board of DirectorsHOLON, Israel, May 13, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced key leadership transitions to take effect in September 2025 following the Annual General Meeting. Anat Cohen-Dayag, Ph.D., currently President and Chief Executive Officer will assume the newly created role of Executive Chair of the Board of Directors, subject

      5/13/25 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

      HOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following

      5/5/25 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEN
    Financials

    Live finance-specific insights

    See more
    • Compugen Reports First Quarter 2025 Results

      Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCOSolid financial position with cash runway expected to fund operations into 2027Key leadership transitions to take effect in September 2025HOLON, Israel, May 19, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage ca

      5/19/25 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

      HOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following

      5/5/25 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • /C O R R E C T I O N -- Compugen Ltd./

      In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q

      3/4/25 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEN
    Leadership Updates

    Live Leadership Updates

    See more

    $CGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

      Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

      2/18/25 8:00:00 AM ET
      $ALLT
      $BLRX
      $CGEN
      $CGNT
      Computer Communications Equipment
      Telecommunications
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compugen Appoints David Silberman as Chief Financial Officer

      HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio

      5/15/24 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

      HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh

      2/15/24 7:00:00 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Compugen with a new price target

      Oppenheimer initiated coverage of Compugen with a rating of Outperform and set a new price target of $4.00

      1/13/25 8:13:52 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compugen downgraded by Jefferies with a new price target

      Jefferies downgraded Compugen from Buy to Hold and set a new price target of $2.00

      8/5/22 7:15:52 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Compugen with a new price target

      Oppenheimer reiterated coverage of Compugen with a rating of Outperform and set a new price target of $14.00 from $17.00 previously

      2/25/22 8:45:50 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

      SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

      2/10/23 10:30:03 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

      SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

      2/3/23 6:10:06 AM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

      SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

      2/9/22 2:26:16 PM ET
      $CGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care